Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISPR-modified PD-1 and ACE2 Knockout T Cells for COVID-19 Immunity
NCT04990557Phase 2Unknown
- Start
- Aug 2021
- Primary completion
- Nov 2022
01
Overview
A Phase 2 trial of PD-1 and ACE2 Knockout T Cells in coronavirus disease 2019 (COVID-19). Status: unknown.
02
Drugs
PD-1 and ACE2 Knockout T Cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04990557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990557.